Finance

Lists
Why is 1541 up 2,58%?
Dive Deeper
1541:HKG
ImmuneOnco Biopharmaceuticals(Shngh) Inc
HK$2,98
+2,58%
(+0,075) 1D
16 āš•.āšĨ., 16 āŧ‚āšĄāš‡ 8 āš™āšēāš—āšĩ 14 āš§āšīāš™āšēāš—āšĩ GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1541...
Open
HK$2,98
High
HK$3,07
Low
HK$2,92
Mkt. cap
1,28 āš•āš·āŧ‰
Avg. vol.
385,40 āšžāšąāš™
Volume
273,40 āšžāšąāš™
52-wk high
HK$11,90
52-wk low
HK$2,80
EPS
HK$-0,63
No. of employees
197
Open
HK$2,98
High
HK$3,07
Low
HK$2,92
Mkt. cap
1,28 āš•āš·āŧ‰
Avg. vol.
385,40 āšžāšąāš™
Volume
273,40 āšžāšąāš™
52-wk high
HK$11,90
52-wk low
HK$2,80
EPS
HK$-0,63
No. of employees
197
News stories
From web sources and news partners
Opening Bell Daily
Opening Bell Daily
·
39 āš™āšēāš—āšĩāšāŧˆāš­āš™
Stock market after midterms: S&P 500 up all 19 times
Simply Wall Street
Simply Wall Street
·
1 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
Aura Minerals (NasdaqGS:AUGO) Shares Just Moved, So What Is Going On?
The Globe and Mail
The Globe and Mail
·
1 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
3 Reasons the Vanguard S&P 500 ETF Could Be Worth Holding for the Next 20 Years
Yahoo Finance
Yahoo Finance
·
11 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
About ImmuneOnco Biopharmaceuticals(Shngh) Inc
CEO-
Employees197
Founded2015
Headquarters-
SectorBiotechnology
Websiteimmuneonco.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
āš.āš. 2025
āš—.āš§. 2025
āšĄ.āš™. 2026
āšĄāšī.āš–. 2026
Revenue
55,14 āšĨāŧ‰āšēāš™
55,14 āšĨāŧ‰āšēāš™
18,62 āšĨāŧ‰āšēāš™
18,62 āšĨāŧ‰āšēāš™
Cost of goods sold
555,00 āšžāšąāš™
555,00 āšžāšąāš™
-
-
Cost of revenue
555,00 āšžāšąāš™
555,00 āšžāšąāš™
-
-
Research and development expenses
77,12 āšĨāŧ‰āšēāš™
77,12 āšĨāŧ‰āšēāš™
77,39 āšĨāŧ‰āšēāš™
77,39 āšĨāŧ‰āšēāš™
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,34 āšĨāŧ‰āšēāš™
13,34 āšĨāŧ‰āšēāš™
11,60 āšĨāŧ‰āšēāš™
11,60 āšĨāŧ‰āšēāš™
Operating expense
90,46 āšĨāŧ‰āšēāš™
90,46 āšĨāŧ‰āšēāš™
88,99 āšĨāŧ‰āšēāš™
88,99 āšĨāŧ‰āšēāš™
Total operating expenses
91,01 āšĨāŧ‰āšēāš™
91,01 āšĨāŧ‰āšēāš™
88,99 āšĨāŧ‰āšēāš™
88,99 āšĨāŧ‰āšēāš™
Operating income
-35,87 āšĨāŧ‰āšēāš™
-35,87 āšĨāŧ‰āšēāš™
-70,36 āšĨāŧ‰āšēāš™
-70,36 āšĨāŧ‰āšēāš™
Other non operating income
4,90 āšĨāŧ‰āšēāš™
4,90 āšĨāŧ‰āšēāš™
-6,50 āšžāšąāš™
-6,50 āšžāšąāš™
EBT including unusual items
-33,27 āšĨāŧ‰āšēāš™
-33,27 āšĨāŧ‰āšēāš™
-82,74 āšĨāŧ‰āšēāš™
-82,74 āšĨāŧ‰āšēāš™
EBT excluding unusual items
-33,47 āšĨāŧ‰āšēāš™
-33,47 āšĨāŧ‰āšēāš™
-77,67 āšĨāŧ‰āšēāš™
-77,67 āšĨāŧ‰āšēāš™
Income tax expense
14,50 āšžāšąāš™
14,50 āšžāšąāš™
11,50 āšžāšąāš™
11,50 āšžāšąāš™
Effective tax rate
-0,04%
-0,04%
-0,01%
-0,01%
Other operating expenses
-
-
-
-
Net income
-33,00 āšĨāŧ‰āšēāš™
-33,00 āšĨāŧ‰āšēāš™
-82,09 āšĨāŧ‰āšēāš™
-82,09 āšĨāŧ‰āšēāš™
Net profit margin
-59,84%
-59,84%
-440,81%
-440,81%
Earnings per share
-
-
-
-
Interest and investment income
1,57 āšĨāŧ‰āšēāš™
1,57 āšĨāŧ‰āšēāš™
2,28 āšĨāŧ‰āšēāš™
2,28 āšĨāŧ‰āšēāš™
Interest expense
-1,43 āšĨāŧ‰āšēāš™
-1,43 āšĨāŧ‰āšēāš™
-2,12 āšĨāŧ‰āšēāš™
-2,12 āšĨāŧ‰āšēāš™
Net interest expenses
136,00 āšžāšąāš™
136,00 āšžāšąāš™
165,50 āšžāšąāš™
165,50 āšžāšąāš™
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,84 āšĨāŧ‰āšēāš™
-33,84 āšĨāŧ‰āšēāš™
-68,41 āšĨāŧ‰āšēāš™
-68,41 āšĨāŧ‰āšēāš™
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
āŧāš­āšąāššāš‚āš­āš‡ Google